Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Atrial tachycardia propafenone

Propafenone Atrial fibrillation, ventricular tachycardia Premature ventricular contractions... [Pg.183]

A 73-year-old woman taking propafenone 150 mg tds for paroxysmal atrial tachycardia underwent cardioversion during an attack, and the dose of propafenone was increased to 300 mg tds. After 5 days she developed severe ataxia and progressive weakness. The ataxia was symmetrical and there was severe impairment of gait, altered hand coordination, and tremor. The dose of propafenone was reduced to 600 mg/day and the ataxia resolved completely within 6 days. A year later, when the dose of propafenone was increased to 900 mg/day, progressive ataxia again developed after 2 days and became severe within 1 week. Propafenone was withdrawn and the ataxia resolved within a few days. [Pg.2941]

Clinical uses PVC, paroxysmal atrial tachycardia, AF, VT Documented life-threatening ventricular arrhythmias. Flecainide also may be used for AF and supraventricular tachycardias in patients without structural heart disease. Propafenone is also indicated for paroxysmal AF. [Pg.7]

Cardiovascular Propafenone, like all class I antidysrhythmic agents, can increase the heart rate in patients with atrial tachydys-rhythmias, because of its vagolytic effect, which leads to enhancement of atrioventricular nodal conduction. A case of propafenone-mediated 1 1 atrial tachycardia has been reported [81 ]. [Pg.389]

Khavandi A, Walker SK. Atrial tachycardia with 1 1 atrioventricular conduction precipitated by propafenone. Emerg Med J 2009 26(12) 904-5. [Pg.396]

The action potential duration and ERP of atrial muscle are both prolonged by propafenone. The electrophysiological effects persist beyond removal of the drug from the tissue. In patients with atrial flutter, fibrillation, or tachycardia, propafenone can slow the atrial rate, resulting in a change from 2 1 or 4 1 A-V block to 1 1 A-V conduction with a subsequent increase in the ventricular rate. [Pg.181]

This agent also has some class lA and class II effects. It is effective for the treatment of ventricular and supraventricular tachycardias (AV nodal and accessory pathway re-entry, atrial flutter and fibrillation). Propafenone is useful in converting recent-onset atrial fibrillation or flutter to sinus rhythm, and for terminating paroxysmal supraventricular tachycardia. Its pro-ariythmic and myocardial depressant effects limit its use, especially in patients with poor ventricular function. [Pg.159]

Amiodarone 30 mg/kg orally for the first 24 hours plus, if necessary, 15 mg/kg over 24 hours has been compared with propafenone 600 mg in the first 24 hours plus, if necessary, 300 mg in the next 24 hours in 86 patients with recent onset atrial fibrillation (31). Conversion to sinus rhythm occurred faster with propafenone (2.4 hours) than amiodarone (6.9 hours). However, by 24 hours and 48 hours the same proportions of patients were in sinus rhythm one patient given amiodarone had a supraventricular tachycardia and one a non-sustained ventricular tachycardia. [Pg.150]

A 57-year-old woman had been taking a formulation containing orphenadrine 15 mg and paracetamol 450 mg bd for musculoskeletal pain. She was also taking propafenone 600 mg/day for paroxysmal atrial fibrillation. After 5 days she developed severe palpitation. Holter monitoring showed frequent brief episodes not only of atrial fibrillation but also of non-sustained ventricular tachycardia. After the orphenadrine was withdrawn the palpitation ceased. [Pg.2641]

Wide-complex tachycardias occurred in two elderly patients (a 74-year-old man and an 80-year-old woman) who had taken propafenone for atrial fibrillation (23). In the first case the dysrhythmia was due to atrial flutter with 1 1 conduction. [Pg.2941]

The safety of oral propafenone in the treatment of dysrhythmias has been studied retrospectively in infants and children (40). There were significant electrophysiolo-gical adverse effects and prodysrhythmia in 15 of 772 patients (1.9%). These included sinus node dysfunction in four, complete atrioventricular block in two, aggravation of supraventricular tachycardia in two, acceleration of ventricular rate during atrial flutter in one, ventricular prodysrhythmia in five, and unexplained sjmcope in one. Cardiac arrest or sudden death occurred in five patients (0.6%) two had a supraventricular tachycardia due to Wolff-Parkinson-White syndrome the other three had structural heart disease. Adverse cardiac events were more common in the presence of structural heart disease and there was no difference between patients with supraventricular and ventricular dysrhythmias. [Pg.2942]

Cobbe SM, Rae AP, Poloniecki ID. A randomized, placebo-controUed trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrUlation. UK Propafenone PSVT Study Group. Circulation 1995 92(9) 2550-7. [Pg.2943]

Propafenone, l- 2-[2-hydroxy-3-(propylamino)propoxy]phenyl -3-phenylpropan-l-one, is a conunonly used sodium and potassium channel blocker for the treatment of ventricular tachycardia and atrial fibrillation [15]. Propafenone hydrochloride is a class IC antiarrhy tmic agent that shows structural similarity and activity related to p-adrenoly tic agents. The drug is efficacious in suppressing supraventricular and ventricular rhythm disorders [15] (Figure 14.12). [Pg.249]


See other pages where Atrial tachycardia propafenone is mentioned: [Pg.389]    [Pg.202]    [Pg.589]    [Pg.600]   


SEARCH



Atrial tachycardia

Propafenone

Propafenones

Tachycardia

© 2024 chempedia.info